List view / Grid view
12 June 2014 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. presented positive results from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis patients who were inadequate responders to methotrexate therapy...
12 June 2014 | By GlaxoSmithKline
Agreement is ViiV Healthcare’s first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine...
12 June 2014 | By AstraZeneca
Phase IIa clinical study to commence in patients with severe asthma...
12 June 2014 | By Amgen
Phase 3 program underway to further assess Brodalumab as potential treatment for people living with psoriatic arthritis...
11 June 2014 | By Novo Nordisk
Up to 2022, Novo Nordisk expects to hire 6,000 new employees in Denmark, half of whom will work within research and development...
11 June 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that a R&D project for a novel, versatile vaccine adjuvant for the purpose of creating a novel vaccine has been awarded a “Newly extended Technology transfer Program”...
11 June 2014 | By AbbVie
AbbVie announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases...
11 June 2014 | By Pfizer
Additional data further characterizes the safety profile of XELJANZ...
11 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced positive results from two phase III studies, which showed that patients with chronic obstructive pulmonary disease who received the anticholinergic, Incruse™ Ellipta®...
11 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced its first release of new data from a Phase IIIb RA trial showing that the T-cell co-stimulation modulator, Orencia...
10 June 2014 | By Novo Nordisk
Novo Nordisk, will unveil 63 abstracts containing safety and efficacy data from our class-leading portfolio of diabetes products at the 74th Annual Scientific Sessions of the American Diabetes Association...
10 June 2014 | By Novartis
The Novartis Foundation for Sustainable Development and Netherlands Leprosy Relief announced their collaboration with national leprosy programs and other International Federation of Anti-Leprosy Associations...
10 June 2014 | By Amgen
Amgen announced the appointment of David W. Meline as executive vice president and chief financial officer, effective July 21, 2014...
9 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced the U.S. Food and Drug Administration has expanded the indication for AZILECT® (rasagiline tablets)...
9 June 2014 | By Merck
Merck and Idenix Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash...
